Advertisement

Topics

Nektar Therapeutics: Encouraging Data Revealed At SITC

02:42 EST 13 Nov 2017 | Topix

Continued updates with these initial treated patients as well as with dose expansion in 13 cohorts should drive future upside. The company appears to be on solid financial footing after the upfront payment received from their collaboration with Eli Lilly.

Original Article: Nektar Therapeutics: Encouraging Data Revealed At SITC

NEXT ARTICLE

More From BioPortfolio on "Nektar Therapeutics: Encouraging Data Revealed At SITC"

Advertisement
Quick Search
Advertisement
Advertisement